Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine that potentiate T cell-mediated cytotoxicity, we identified atractylenolide I (ATT-I), which substantially promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non-ATPase 4 (PSMD4), an essential component of the immunoproteasome complex, as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigen-processing activity of immunoproteasome, leading to enhanced MHC-I-mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient-derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation and empowers T cell cytotoxicity, thus elevating the tumor response to immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408 · cited 1×
“reported for generation of colorectal tumor organoids (42).”
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · cited 1×
“D, Supple-mental Figure 2A) (20).”
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · cited 1×
“In addition to therapeutic antibodies and immune system modulators, adoptive cell transfer and immune checkpoint inhibitors are among the most promising approaches in human cancer therapies (10, 11).”
Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005 · cited 3×
“…immune checkpoint blockade therapies revealed a correlation of point mutations, deletions or loss of heterozygosity in the β -2- microglobulin ( B2M ) gene, which encodes an essential component of the MHC-I antigen presentation complex, with therapeutic resistance and poor clinical outcomes (2).”
Complete subunit architecture of the proteasome regulatory particle
Lander, G. C., Estrin, E., Matyskiela, M. E., Bashore, C., Nogales, E., & Martin, A. (2012) · Nature · doi:10.1038/nature10774 · Cited by 608 · cited 1×
“The proteasome 26S subunit non-ATPase 4 (PSMD4) is an essential component of the 19S regulator lid in the 26S immuno-proteasome complex that processes MHC-I–associated antigen peptides (21–23).”
Drug resistance and new therapies in colorectal cancer
Jeught, K. V. D., Xu, H.-C., Li, Y.-J., Lu, X.-B., & Ji, G. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i34.3834 · Cited by 597 · cited 1×
“MC38, HCT116, and SW837 cells were maintained in DMEM supplemented with 10% FBS (Sigma-Al-tially expand the number of CRC patients sensitive to checkpoint immunotherapy, which is a primary focus in clinical development (13).”
Self-citation
Cited by
Tu, Y., Tan, L., Tao, H., Li, Y., & Liu, H. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154862 · Cited by 190
Self-citationOrganoid co‐culture models of the tumor microenvironment promote precision medicine
Gu, Z., Wu, Q., Shang, B., Zhang, K., & Zhang, W. (2024) · Cancer Innovation · doi:10.1002/cai2.101 · Cited by 47
“Furthermore, there has been a study in which co ‐ culture models were used to screen for small ‐ molecule compounds that enhance the immune response [137].”
BackgroundMethodColorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
An overview on nanoplatforms for statins delivery: Perspectives for safe and effective therapy
Etemad, L., Salmasi, Z., Moosavian Kalat, S. A., Moshiri, M., Zamanian, J., Kesharwani, P., & Sahebkar, A. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116572 · Cited by 18
Metadata
- Authors
- Xu, H., Van der Jeught, K., Zhou, Z., Zhang, L., Yu, T., Sun, Y., Li, Y., Wan, C., So, K. M., Liu, D., Frieden, M., Fang, Y., Mosley, A. L., He, X., Zhang, X., Sandusky, G. E., Liu, Y., Meroueh, S. O., Zhang, C., Wijeratne, A. B., Huang, C., Ji, G., & Lu, X.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-05-17
- Volume
- 131
- Issue
- 10
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3147809641
- Cited by
- 160
- References
- 11
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.